Ridhima Goel, Alessandro Spirito, Michael Gao, Birgit Vogel, Deborah N Kalkman, Roxana Mehran
{"title":"Second-generation everolimus-eluting intracoronary stents: a comprehensive review of the clinical evidence.","authors":"Ridhima Goel, Alessandro Spirito, Michael Gao, Birgit Vogel, Deborah N Kalkman, Roxana Mehran","doi":"10.2217/fca-2023-0092","DOIUrl":null,"url":null,"abstract":"<p><p>Percutaneous coronary intervention with implantation of second-generation drug-eluting stents (DES) has emerged as a mainstay for the treatment of obstructive coronary artery disease given its beneficial impact on clinical outcomes in these patients. Everolimus-eluting stents (EES) are one of the most frequently implanted second-generation DES; their use for the treatment of a wide range of patients including those with complex coronary lesions is supported by compelling evidence. Although newer stent platforms such as biodegradable polymer DES may lower local vessel inflammation, their efficacy and safety have not yet surpassed that of Xience stents. This article summarizes the properties of the Xience family of EES and the evidence supporting their use across diverse patient demographics and coronary lesion morphologies.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"103-116"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216266/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/fca-2023-0092","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Percutaneous coronary intervention with implantation of second-generation drug-eluting stents (DES) has emerged as a mainstay for the treatment of obstructive coronary artery disease given its beneficial impact on clinical outcomes in these patients. Everolimus-eluting stents (EES) are one of the most frequently implanted second-generation DES; their use for the treatment of a wide range of patients including those with complex coronary lesions is supported by compelling evidence. Although newer stent platforms such as biodegradable polymer DES may lower local vessel inflammation, their efficacy and safety have not yet surpassed that of Xience stents. This article summarizes the properties of the Xience family of EES and the evidence supporting their use across diverse patient demographics and coronary lesion morphologies.
植入第二代药物洗脱支架（DES）的经皮冠状动脉介入治疗已成为治疗阻塞性冠状动脉疾病的主要方法，因为它对这些患者的临床疗效产生了有益的影响。依维莫司洗脱支架（EES）是最常用的第二代药物洗脱支架之一；其用于治疗包括复杂冠状动脉病变患者在内的各类患者得到了有力证据的支持。虽然生物可降解聚合物 DES 等新型支架平台可降低局部血管炎症，但其有效性和安全性尚未超过 Xience 支架。本文总结了 Xience 系列 EES 的特性，以及支持其在不同患者人口统计学和冠状动脉病变形态中使用的证据。
期刊介绍：
Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
